Rimonabant + Placebo (for Rimonabant)
Phase 3Terminated 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Carotid Artery Plaque
Conditions
Carotid Artery Plaque, Arteriosclerosis, Obesity, Metabolic Syndrome X
Trial Timeline
Aug 1, 2005 โ Apr 1, 2009
NCT ID
NCT00228176About Rimonabant + Placebo (for Rimonabant)
Rimonabant + Placebo (for Rimonabant) is a phase 3 stage product being developed by Sanofi for Carotid Artery Plaque. The current trial status is terminated. This product is registered under clinical trial identifier NCT00228176. Target conditions include Carotid Artery Plaque, Arteriosclerosis, Obesity.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00577148 | Phase 3 | Terminated |
| NCT00576667 | Phase 3 | Terminated |
| NCT00478972 | Phase 3 | Terminated |
| NCT00325650 | Phase 3 | Terminated |
| NCT00299325 | Phase 3 | Completed |
| NCT00263042 | Phase 3 | Terminated |
| NCT00228176 | Phase 3 | Terminated |
Competing Products
9 competing products in Carotid Artery Plaque
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abciximab | Eli Lilly | Phase 1/2 | 41 |
| Rosuvastatin | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin (5mg๏ผ10mg๏ผ20mg) + Rosuvastatin 5mg | AstraZeneca | Approved | 85 |
| Niacin/simvastatin compared to simvastatin alone at 2 doses | Merck | Approved | 85 |
| simvastatin + placebo | Merck | Pre-clinical | 23 |
| Atorvastatin/niacin extended-release + Atorvastatin + Simvastatin + Simvastatin | Merck | Phase 2 | 52 |
| Evolocumab | Amgen | Approved | 84 |
| Atorvastatin - Cholestyramine - Sitosterol | Pfizer | Pre-clinical | 22 |
| Gadobutrol (Gadovist, BAY86-4875) | Bayer | Phase 3 | 74 |